Qiagen logged a 0.1% change during today's afternoon session, and is now trading at a price of $46.87 per share.
Qiagen returned losses of -524.2% last year, with its stock price reaching a high of $51.18 and a low of $40.38. Over the same period, the stock underperformed the S&P 500 index by -1741.0%. As of April 2023, the company's 50-day average price was $45.69. QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. Based in Venlo, Netherlands, the large-cap Health Care company has 6,200 full time employees. Qiagen has not offered a regular dividend during the last year.
Wider Gross Margins Than the Industry Average of 57.74%:
| 2020-03-02 | 2021-03-05 | 2022-03-14 | 2023-03-13 | |
|---|---|---|---|---|
| Revenue (MM) | $1,526 | $1,870 | $2,252 | $2,142 |
| Gross Margins | 65.9% | 65.9% | 64.4% | 64.6% |
| Operating Margins | 20.6% | 29.8% | 30.0% | 27.6% |
| Net Margins | -2.72% | 19.2% | 22.77% | 19.76% |
| Net Income (MM) | -$41 | $359 | $513 | $423 |
| Net Interest Expense (MM) | -$52 | -$61 | -$45 | -$26 |
| Depreciation & Amort. (MM) | -$231 | -$205 | -$215 | -$208 |
| Earnings Per Share | -$0.18 | $1.58 | $2.25 | $1.53 |
| EPS Growth | n/a | 977.78% | 42.41% | -32.0% |
| Diluted Shares (MM) | 227 | 228 | 228 | 228 |
| Free Cash Flow (MM) | $606 | $762 | $846 | $865 |
| Capital Expenditures (MM) | -$275 | -$304 | -$207 | -$149 |
| Net Current Assets (MM) | -$1,129 | -$1,685 | -$941 | -$427 |
| Current Ratio | 1.65 | 2.42 | 1.39 | 2.46 |
| Long Term Debt (MM) | $1,421 | $1,880 | $1,094 | $1,472 |
| Net Debt / EBITDA | 3.89 | 2.43 | 1.61 | 1.99 |
Qiagen has strong margins with a positive growth rate, exceptional EPS growth, and a steady stream of strong cash flows. The company also benefits from an excellent current ratio, growing revenues and decreasing reinvestment in the business, and wider gross margins than its peer group.
A Lower P/B Ratio Than Its Sector Average but Trades Above Its Graham Number:
Qiagen has a trailing twelve month P/E ratio of 29.9, compared to an average of 24.45 for the Health Care sector. Based on its EPS guidance of $2.3, the company has a forward P/E ratio of 19.9. According to the 69.0% compound average growth rate of Qiagen's historical and projected earnings per share, the company's PEG ratio is 0.43. Taking the weighted average of the company's EPS CAGR and the broader market's 5-year projected EPS growth rate, we obtain a normalized growth rate of 11.5%. On this basis, the company's PEG ratio is 2.6. This suggests that these shares are overvalued. In contrast, the market is likely undervaluing Qiagen in terms of its equity because its P/B ratio is 3.0 while the sector average is 4.16. The company's shares are currently trading 119.3% above their Graham number. In conclusion, Qiagen's impressive cash flow trend, decent P/B ratio, and reasonable use of leverage demonstrate that the company may still be fairly valued — despite its elevated earnings multiple.
Analysts Give Qiagen an Average Rating of Buy:
The 13 analysts following Qiagen have set target prices ranging from $42.5 to $64.0 per share, for an average of $53.17 with a buy rating. As of April 2023, the company is trading -14.1% away from its average target price, indicating that there is an analyst consensus of some upside potential.
Qiagen has a very low short interest because 1.8% of the company's shares are sold short. Institutions own 73.7% of the company's shares, and the insider ownership rate stands at 0.37%, suggesting a small amount of insider investors. The largest shareholder is Massachusetts Financial Services Co., whose 9% stake in the company is worth $993,479,557.
